{"id":72014,"date":"2026-07-31T19:22:29","date_gmt":"2026-07-31T17:22:29","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/07\/31\/immune-hallmarks-of-recurrent-immune-checkpoint-inhibitor-mediated-inflammatory-arthritis\/"},"modified":"2026-07-31T19:22:29","modified_gmt":"2026-07-31T17:22:29","slug":"immune-hallmarks-of-recurrent-immune-checkpoint-inhibitor-mediated-inflammatory-arthritis","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/07\/31\/immune-hallmarks-of-recurrent-immune-checkpoint-inhibitor-mediated-inflammatory-arthritis\/","title":{"rendered":"Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Jul 31. doi: 10.1158\/2326-6066.CIR-25-1639. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Immune checkpoint inhibitor (ICI) therapy is often associated with immune-related adverse events including inflammatory arthritis (ICI-IA). However, the mechanisms underlying ICI-IA, especially its recurrence, are not well understood. In this study, we sought to elucidate mechanisms of recurrent ICI-IA by analyzing longitudinal synovial fluid (SF) samples from patients with ICI-IA. SF samples were collected from six ICI-IA patients at the first and second occurrences of ICI-IA and analyzed with single-cell RNA sequencing (n=3), single-cell TCR sequencing (n=3), single-cell BCR sequencing (n=3), and flow cytometry (n=6). SF samples from cancer-na\u00efve osteoarthritis patients (n=6) were used as negative controls. Analysis revealed that effector CD8+ T cells and PD-1hiCXCL13hiCD4+ T cells were enriched in the SF of ICI-IA patients. Ninety three percent and fifty percent of the top ten expanded clones of effector CD8+ T cells and PD-1hiCXCL13hiCD4+ T cells, respectively, were shared between the first and second ICI-IA flare. These top clones were characterized by the production of pro-inflammatory type 1 cytokines including IFN\uf067, TNF\uf061, and IL-21, especially in the second flare, suggesting immune memory responses to cognate antigen. Cell-cell communication analysis suggested that effector CD8+ T cells and PD-1hiCXCL13h CD4+ T cells interacted with each other and with myeloid cells and B cells through chemokines (CXCL9\/10\/11\/13, CCL3) and cytokines (MIF, IL-2\/7\/15\/21). Overall, longitudinal SF analysis from ICI-IA patients revealed the expansion of effector CD8+ T cells and PD-1hiCXCL13hiCD4+ T cells with type 1 cytokine signatures that potentially contribute to development or recurrence of ICI-IA.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42536056\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260731132228&amp;v=2.20.0.post5+40e1b98\">42536056<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-1639\">10.1158\/2326-6066.CIR-25-1639<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Jul 31. doi: 10.1158\/2326-6066.CIR-25-1639. Online ahead of print. ABSTRACT Immune checkpoint inhibitor (ICI) therapy is often associated with immune-related adverse events including inflammatory arthritis (ICI-IA). However, the mechanisms underlying ICI-IA, especially its recurrence, are not well understood. In this study, we sought to elucidate mechanisms of recurrent ICI-IA by analyzing longitudinal &#8230; <a title=\"Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/31\/immune-hallmarks-of-recurrent-immune-checkpoint-inhibitor-mediated-inflammatory-arthritis\/\" aria-label=\"Read more about Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-72014","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/72014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=72014"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/72014\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=72014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=72014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=72014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}